Please Wait.....
Report
Breast Cancer Therapy Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)
Market Report I 2023-01-23 I 120 Pages I Mordor Intelligence
The breast cancer therapy market is expected to record a CAGR of 8.3% over the forecast period (2022-2027).
Following the outbreak of COVID-19, the market has faced a slight setback, owing to the delay in diagnoses, shortages of drugs, and unavailability of healthcare professionals. According to an article published in the JAMA Network in August 2020, there was a significant decline in breast cancer diagnoses (51.8%) in the United States between March 1, 2020, and April 18, 2020. This delay in diagnosis has impacted the treatment of the same. However, the market is expected to gain traction over the coming years as treatments resume worldwide.
The major factors fueling the market's growth are the high incidence and prevalence rates of breast cancer; increasing investment in research and development; and advancements in cancer biology and pharmacology, which are promoting drug development.
According to Globocan, in 2020, about 2,261,419 new cases of cancer were reported across the world, contributing to about 11.7% of the total cancer cases. As per Cancer Australia, in 2021, it was estimated that 20,030 new cases of breast cancer were diagnosed in the country (164 males and 19,866 females). The same source reports that in 2021, a person had an estimated 1 in 15 (or 6.7%) risk of being diagnosed with breast cancer by the age of 85 (1 in 8 or 13% for females and 1 in 829 or 0.12% for males). Therefore, the high burden of breast cancer is increasing the demand for breast cancer treatment, thereby contributing to the market's growth.
The increasing focus of research studies by the market players. For instance, in September 2021, Novartis collaborated with SOLTI Innovative Cancer Research (SOLTI) on HARMONIA, an international, randomized, Phase III, multicenter, and open-label study of Kisqali (ribociclib) versus Ibrance (palbociclib), both in combination with endocrine therapy. This study was done on patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with a HER2-enriched (HER2E) intrinsic subtype.
Additionally, in July 2021, Arvinas Inc. and Pfizer Inc. collaborated to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers.
On the other hand, the risk of adverse effects of radiation exposure and stringent regulatory scenarios are hindering the market's growth.
Breast Cancer Therapy Market Trends
Chemotherapy Segment Expected to Witness High Growth Over the Forecast Period
Chemotherapy is the most common form of therapy used to stop or slow down the growth of cancerous cells. It is the most common treatment for triple-negative breast cancer patients.
According to the Centers for Disease Control and Prevention, in a November 2021 update, nearly 650,000 cancer patients (including breast cancer patients) receive chemotherapy every year in the United States. Thus, the growing number of patients receiving chemotherapy and the development of new products are expected to significantly contribute to the market's growth.
Furthermore, the number of product launches in this segment is expected to drive its growth. For instance, in July 2021, Merck, also known as MSD outside the United States and Canada, announced that the United States Food and Drug Administration (FDA) approved KEYTRUDA, Merck's anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC). Based on Phase 3 KEYNOTE-522 trial, this is meant to be used in combination with chemotherapy as a neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery. Also, in May 2021, Zydus Cadila launched a next-generation breast cancer drug in India. The drug, Trastuzumab emtasine, is considered the first targeted chemotherapy drug for breast cancer.
Thus, owing to the abovementioned factors, the market segment is expected to show growth over the forecast period.
North America Expected to Dominate the Market Over the Forecast Period
Within North America, the United States is expected to dominate the overall market throughout the forecast period. The major factors fueling the market's growth are the increasing burden of breast cancer in the country, growing awareness about breast cancer, and increasing product launches.
In the United States, breast cancer is one of the leading cancer types. According to the January 2022 update by breastcancer.org, around 1 in 8 women in the country (about 13%) develop invasive breast cancer over their lifetime. The same source reports that, in 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the United States, as well as 51,400 new cases of non-invasive (in situ) breast cancer. As per the same source, about 2,710 new cases of invasive breast cancer are expected to be diagnosed in men in 2022. A man's lifetime risk of breast cancer is about 1 in 833.
Furthermore, as per an October 2021 update by the University of North Carolina's School of Medicine, Susan G. Komen, the world's leading breast cancer organization, announced that it would award USD 1.5 million for three new research projects that examine three unique areas focused on metastatic breast cancer (MBC).
In April 2021, Gilead Sciences Inc. reported that the United States Food and Drug Administration (FDA) granted full approval to Trodelvy (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
Thus, due to the above-mentioned factors, the market in North America is expected to grow during the forecast period.
Breast Cancer Therapy Market Competitor Analysis
The breast cancer therapy market is competitive and consists of several major and small players. Some of the major players in the market are Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Eisai Co. Ltd., and Merck & Co. Inc.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Incidence and Prevalence Rate of Breast Cancer
4.2.2 Increasing Investments in R&D
4.2.3 Advancements in Cancer Biology and Pharmacology, Promoting Drug Development
4.3 Market Restraints
4.3.1 Risk of Adverse Effects of Radiation Exposure
4.3.2 Stringent Regulatory Scenarios
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Therapy
5.1.1 Radiation Therapy
5.1.2 Targeted Therapy
5.1.2.1 Herceptin
5.1.2.2 Tykerb (Lapatinib)
5.1.2.3 Afinitor
5.1.2.4 Other Targeted Therapies
5.1.3 Hormonal Therapy
5.1.3.1 Selective Estrogen - Receptor Modulators
5.1.3.2 Aromatase Inhibitors
5.1.3.3 Other Hormonal Therapies
5.1.4 Chemotherapy
5.1.4.1 Taxanes
5.1.4.2 Anthracyclines
5.1.4.3 Anti-metabolites
5.1.4.4 Alkylating Agents
5.1.4.5 Epothilones
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca PLC
6.1.2 Bristol-Myers Squibb Company
6.1.3 Eisai Co. Ltd
6.1.4 Eli Lilly and Company
6.1.5 Genentech
6.1.6 GlaxoSmithKline PLC
6.1.7 Halozyme Inc.
6.1.8 Novartis AG
6.1.9 Pfizer Inc.
6.1.10 Hikma Pharmaceuticals
6.1.11 Baxter Healthcare Corporation
6.1.12 FRESENIUS KABI
6.1.13 Teva Pharmaceutical Industries Ltd
6.1.14 Celltrion
6.1.15 Myan Laboratories
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security